



Alnylam to Webcast R&D Day

November 29, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 29, 2018-- [Alnylam Pharmaceuticals, Inc.](http://www.alnylam.com) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the Company's website, www.alnylam.com, on the morning of December 6, 2018.

Alnylam management and key opinion leaders will discuss late-stage clinical efforts, as well as next wave programs and platform advances, for the Company's RNAi therapeutics pipeline. The event will include presentations from the following guest speakers:

- John D. Phillips, Ph.D.
Professor of Medicine, Division of Hematology, University of Utah
- Sally-Anne Hulton, M.D.
Paediatric Nephrologist, Birmingham Women's and Children's Hospital

The meeting will be held on Thursday, December 6, 2018 from 8:00 am to 1:00 pm ET at the Westin New York at Times Square in New York City. A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform. Alnylam's first U.S. FDA-approved RNAi therapeutic is ONPATTRO™ (patisiran) lipid complex injection available in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. In the EU, ONPATTRO is approved for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. Alnylam has a deep pipeline of investigational medicines, including four product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 1,000 people worldwide and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at [@Alnylam](https://twitter.com/Alnylam) or on [LinkedIn](https://www.linkedin.com/company/alnylam).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181129005059/en/>

Source: Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom
(Investors and Media)
617-682-4340

Josh Brodsky
(Investors)
617-551-8276